跳转至内容
Merck
CN

UHPLC Analysis of Intact Infliximab on BIOshell IgG 1000 Å C4

UHPLC Analysis of Intact Infliximab on BIOshell™ IgG 1000 Å C4 application for UHPLC

材料

used together

产品编号
说明
价格

Acetonitrile

suitable for HPLC, gradient grade, ≥99.9%

1-Butanol

suitable for HPLC, ≥99.7%

Trifluoroacetic acid

≥99%, for protein sequencing

相关产品

产品编号
说明
价格

SILuMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody

recombinant, expressed in CHO cells

BIOshell lgG 1000 Å C4, 2.7 μm HPLC Column

2.7 μm particle size, L × I.D. 10 cm × 2.1 mm

CONDITIONS

column

BIOshell IgG 1000 Å C4; 10 cm x 2.1 mm I.D., 2.7 μm particles (63288-U)

mobile phase

[A] 70:25:5, water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA); [B] 50:45:5, water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA)

gradient

0% B to 100% B in 15 min

flow rate

0.2 mL/min

pressure

1800 psi (122 bar)

column temp.

75 °C

detector

UV, 215 nm

injection

5 μL

sample

Infliximab, 100 μg/mL, water (0.05% TFA)

说明

分析说明

Infliximab (brand name Remicade) is an immunosuppressive biologic drug used to treat rheumatoid arthritis, psoriatic arthritis, Crohn′s disease, and many other diseases by blocking TNF alpha which prevents an autoimmune reaction. It has a molecular weight of ~150 kDa. The BIOshell IgG 1000 Å C4 UHPLC column yielded an efficient peak for this protein in less than five minutes.

法律信息

BIOshell is a trademark of Sigma-Aldrich Co. LLC